Navigation Links
Novel Technology Breaks Through Cancer Pain

MORRISVILLE, N.C., Aug. 16 /PRNewswire/ -- Cancer patients fraught with flare-ups of pain, or breakthrough pain, may soon receive some assistance in the form of a new easy-to-use oral drug delivery system developed by BioDelivery Sciences designed to quickly deliver pain medication.

Cancer patients frequently experience two types of pain: persistent and breakthrough. Persistent cancer pain is characterized as continuous pain present for long periods of time, and often most of the day. Persistent pain is treated by daily or regular doses of pain medication.

Breakthrough pain is a brief and often severe shooting of pain that "breaks through" a patient's continuous medication for persistent pain. Breakthrough pain often has a rapid onset and lasts a short duration of time. It is called breakthrough pain because it "breaks through" a regular pain medicine schedule.

"Breakthrough pain is caused either by the cancer itself or the cancer treatment. For some patients, the pain is connected to certain activities, such as walking or dressing. For others, it occurs unexpectedly," says Dr. Andrew Finn, BioDelivery Sciences' VP of Product Development.

One breakthrough pain medication is the opiate fentanyl. Fentanyl is a potent opioid analgesic (painkiller) first developed in the 1950s, and long in use by the medical community for controlling various types of pain.

The next generation product able to quickly deliver fentanyl for the treatment of cancer breakthrough pain is a patient-friendly, small oral adhesive disc called BEMA Fentanyl, which has recently completed Phase III trials by BioDelivery Sciences. The BEMA technology is a very small layered disc that is applied to a mucosal surface (inner lining of the mouth) in a similar way a transdermal disc is applied to the skin.

The small disc is composed of an adhesive layer and a non-adhesive backing layer. The disc adheres to the inside cheeks and delivers the dose of medication quickly into the bloodstream. Instead of requiring removal upon completion of the drug delivery, the BEMA disc disintegrates in the mouth and leaves no drug residue.

The results of the Phase III pivotal efficacy clinical trial in cancer patients with breakthrough pain announced earlier this year with BEMA Fentanyl are very encouraging.

"The results of our study demonstrated that fentanyl could be delivered rapidly, effectively and easily using the BEMA technology," said Finn. "Besides allowing greater absorption of fentanyl, the BEMA disc was easier to use, as it only required seconds to apply."

It is estimated that at least 60 percent of people with advanced cancer will experience significant pain of some type, oftentimes including breakthrough pain. For more information on BEMA Fentanyl, log on to

SOURCE BioDelivery Sciences

Copyright©2007 PR Newswire.

Related medicine technology :

1. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
2. Anacor Identifies a Novel Mechanism for Its Lead Anti-Fungal Drug, AN2690; Findings Published in Science
3. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
4. Prolexys Pharmaceuticals and Columbia University Researchers Publish Study on Anti-Tumor Properties of a Selective Small Molecule Anti-Tumor Agent With Novel Mechanism of Action
5. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
6. Novel Mechanism Insights and Additional Data on CombinatoRx Drug Candidates to Be Presented at Upcoming EULAR Meeting
7. Roxro Pharma’s Novel Intranasal Pain Reliever Effective, Well Tolerated in Phase 3 Study
8. Anacor Clinical Study of AN2728, a Novel Anti-Inflammatory Compound, Shows Efficacy in Psoriasis
9. Metabasis Therapeutics Presents Results of Preclinical Studies for MB07811, Its Novel Product Candidate for the Treatment of Hyperlipidemia, at the Endocrine Societys Annual Meeting
10. Encouraging Clinical Activity of GSKs Novel Cancer Immunotherapeutic Confirmed in Phase II Study in Patients with Most Common Form of Lung Cancer
11. Clinical Data on ARIADs Novel mTOR Inhibitor, AP23573, To Be Presented at the ASCO Annual Meeting
Post Your Comments:
(Date:12/1/2015)... , Dec. 01, 2015 ... the addition of the "Spinal Muscular ... Trends, and Forecast 2015 - 2023" ... ) has announced the addition of ... Pipeline Assessment, Size, Growth, Trends, and Forecast ...
(Date:12/1/2015)... , Dec. 1, 2015  Eyeon Therapeutics ... novel dry eye treatments based on a charged ... drug delivery CDMO.  The product has been shown ... trial previously published.  Mark Mitchnick , MD, ... the protection to additional polymers in conjunction with ...
(Date:12/1/2015)... , Dec. 1, 2015  Athletic apparel ... founder have agreed to pay $1.35 million to ... advertised the company,s copper-infused compression clothing would relieve ... arthritis and other diseases. Tommie ... requires the company and its founder and chairman ...
Breaking Medicine Technology:
(Date:12/1/2015)... , ... December 01, 2015 , ... ... website detailing the important role that meat and poultry play in a ... and poultry, a nutrition quiz where visitors can check their “meat IQ,” a ...
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... ... firm, has announced its acquisition by Jordan Industries International, LLC (“JII”). , With ... of equipment rentals and maintenance services to hospitals, surgery centers, clinics, research labs ...
(Date:12/1/2015)... ... December 01, 2015 , ... Califia Farms , ... that its iconic bottle has won top honors in Beverage World Magazine’s Global Packaging ... also announced that it has been selected as a 2015 U.S.A. Taste Champion in ...
(Date:12/1/2015)... NY (PRWEB) , ... December 01, 2015 , ... ... in the 1980s we have seen vast improvements in scientific research and discoveries, ... significant strides, providing increased hope and relief to those affected by HIV/AIDS. Mediaplanet’s ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... of adjunctive imaging is the focus of numerous abstracts accepted for presentation here, ... 4, 2015. Nine abstracts highlight the use of Volpara Solutions’ quantitative breast ...
Breaking Medicine News(10 mins):